EA202192792A1 - Композиция для пероральной доставки белков, пептидов и малых молекул со слабой проницаемостью - Google Patents

Композиция для пероральной доставки белков, пептидов и малых молекул со слабой проницаемостью

Info

Publication number
EA202192792A1
EA202192792A1 EA202192792A EA202192792A EA202192792A1 EA 202192792 A1 EA202192792 A1 EA 202192792A1 EA 202192792 A EA202192792 A EA 202192792A EA 202192792 A EA202192792 A EA 202192792A EA 202192792 A1 EA202192792 A1 EA 202192792A1
Authority
EA
Eurasian Patent Office
Prior art keywords
composition
oral delivery
peptides
proteins
small molecules
Prior art date
Application number
EA202192792A
Other languages
English (en)
Inventor
Венсан Пласса
Бенуа Ильболь
Орелия Галю
Тома Пуанто
Жюльен Мейссоннье
Original Assignee
Ар.Пи. ШЕРЕР ТЕКНОЛОДЖИЗ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ар.Пи. ШЕРЕР ТЕКНОЛОДЖИЗ, ЭлЭлСи filed Critical Ар.Пи. ШЕРЕР ТЕКНОЛОДЖИЗ, ЭлЭлСи
Publication of EA202192792A1 publication Critical patent/EA202192792A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к фармацевтической композиции, предназначенной для пероральной доставки синтетических или природных молекул со слабой проницаемостью, или их солей/сольватов, обладающих терапевтической активностью. Фармацевтическая композиция может включать синтетическую или природную молекулу со слабой проницаемостью, или ее соль или сольват, в количестве 0,01-10 мас.% от общей массы композиции; липофильную фазу, содержащую триглицериды жирных кислот в количестве 50-80 мас.% от общей массы композиции; и по меньшей мере одно липофильное поверхностно-активное вещество, содержащее неполные эфиры полиола и жирных кислот в количестве около 10-50 мас.% от общей массы композиции.
EA202192792A 2019-04-11 2020-04-10 Композиция для пероральной доставки белков, пептидов и малых молекул со слабой проницаемостью EA202192792A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832508P 2019-04-11 2019-04-11
PCT/US2020/027801 WO2020210723A1 (en) 2019-04-11 2020-04-10 Formulation for oral delivery of proteins, peptides and small molecules with poor permeability

Publications (1)

Publication Number Publication Date
EA202192792A1 true EA202192792A1 (ru) 2022-01-11

Family

ID=70476554

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202192792A EA202192792A1 (ru) 2019-04-11 2020-04-10 Композиция для пероральной доставки белков, пептидов и малых молекул со слабой проницаемостью
EA202192793A EA202192793A1 (ru) 2019-04-11 2020-04-10 Композиция для пероральной доставки белков, пептидов и малых молекул со слабой проницаемостью

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202192793A EA202192793A1 (ru) 2019-04-11 2020-04-10 Композиция для пероральной доставки белков, пептидов и малых молекул со слабой проницаемостью

Country Status (16)

Country Link
US (3) US20220249468A1 (ru)
EP (2) EP3952899A1 (ru)
JP (2) JP2022526833A (ru)
KR (2) KR20210151185A (ru)
CN (2) CN113784722A (ru)
AR (1) AR118654A1 (ru)
AU (2) AU2020272059A1 (ru)
BR (2) BR112021020287A2 (ru)
CA (2) CA3134550A1 (ru)
CO (2) CO2021012462A2 (ru)
EA (2) EA202192792A1 (ru)
IL (2) IL287084A (ru)
MX (2) MX2021012354A (ru)
SG (2) SG11202111251SA (ru)
WO (2) WO2020210723A1 (ru)
ZA (1) ZA202108909B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116456981A (zh) * 2020-11-19 2023-07-18 辉瑞爱尔兰制药公司 用于改善的grp抑制剂递送的组合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
EP0684834A4 (en) * 1993-02-17 1996-09-25 Smithkline Beecham Corp MICROEMULSIONS CONTAINING THERAPEUTIC PEPTIDES.
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
FR2803203B1 (fr) * 1999-12-31 2002-05-10 Fournier Ind & Sante Nouvelles formulations galeniques du fenofibrate
CZ20032225A3 (cs) 2001-02-27 2003-11-12 Astrazeneca Ab Farmaceutická formulace
CZ20033341A3 (cs) * 2001-06-21 2004-10-13 Pfizeráproductsáinc Samoemulgující se kompozice inhibitorů přenosového proteinu cholesterylesteru
WO2003047493A2 (en) * 2001-12-03 2003-06-12 Dor Biopharma Inc. Stabilized reverse micelle compositions and uses thereof
CA2487976C (en) 2002-06-05 2011-07-26 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US20050249802A1 (en) 2004-05-06 2005-11-10 The Procter & Gamble Company Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients
CN101048137A (zh) * 2004-10-29 2007-10-03 诺瓦提斯公司 可自发分散的药物组合物
CN101065115A (zh) * 2004-11-24 2007-10-31 默克公司 取代酰胺的液体和半固体口服药物制剂
US20080014274A1 (en) 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
WO2008030524A2 (en) * 2006-09-08 2008-03-13 Merck & Co., Inc. Liquid pharmaceutical formulations for oral administration of a cgrp antagonist
CN105688191A (zh) * 2007-04-23 2016-06-22 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
US8323695B2 (en) 2007-08-13 2012-12-04 Mcneil-Ppc, Inc. Method for stabilizing phenylephrine
KR20100058550A (ko) * 2007-09-11 2010-06-03 몬도바이오테크 래보래토리즈 아게 녹농균 감염 치료시 치료제로서의 밴드 ３ 단백질 （８２４－８２９） 및／또는 멜라닌세포－자극 호르몬 방출－저해 인자의 용도
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
CA2784529C (en) * 2009-12-18 2018-05-22 Catalent France Beinheim Sa Pharmaceutical oral dosage form containing a synthetic oligosaccharide
US8481546B2 (en) * 2010-03-30 2013-07-09 Bristol-Myers Squibb Company CGRP receptor antagonist
KR102201607B1 (ko) * 2012-05-18 2021-01-12 제넨테크, 인크. 고농도 모노클로날 항체 제제
SG11201505607SA (en) 2013-02-28 2015-09-29 Pfizer Enhanced stability of novel liquid compositions
US8859623B1 (en) 2013-11-14 2014-10-14 Paragon BioTeck, Inc. Methods and compositions of stable phenylephrine formulations
JP2017515852A (ja) * 2014-05-16 2017-06-15 ソーク インスティテュート フォー バイオロジカル スタディーズ 代謝障害を処置するための組成物および方法
CA3001337C (en) 2015-10-09 2023-12-12 Reckitt Benckiser Llc Pharmaceutical formulation
WO2017093810A2 (en) * 2015-10-14 2017-06-08 Pharcon Inc. Composition for intraoral delivery of biologically active peptides and proteins

Also Published As

Publication number Publication date
SG11202110546UA (en) 2021-10-28
US20200323985A1 (en) 2020-10-15
BR112021020287A2 (pt) 2021-12-14
CA3134550A1 (en) 2020-10-15
CA3136485A1 (en) 2020-10-15
MX2021012356A (es) 2021-11-04
CN113784722A (zh) 2021-12-10
KR20210151187A (ko) 2021-12-13
BR112021018817A2 (pt) 2021-11-23
WO2020210722A1 (en) 2020-10-15
CO2021012462A2 (es) 2021-09-30
CO2021014899A2 (es) 2021-11-19
US20220143188A1 (en) 2022-05-12
AR118654A1 (es) 2021-10-20
US11185589B2 (en) 2021-11-30
WO2020210723A1 (en) 2020-10-15
SG11202111251SA (en) 2021-11-29
AU2020272059A1 (en) 2021-12-09
MX2021012354A (es) 2021-10-22
JP2022526833A (ja) 2022-05-26
IL287131A (en) 2021-12-01
KR20210151185A (ko) 2021-12-13
EA202192793A1 (ru) 2022-01-12
ZA202108909B (en) 2022-07-27
JP2022526196A (ja) 2022-05-23
EP3952900A1 (en) 2022-02-16
US20220249468A1 (en) 2022-08-11
TW202103726A (zh) 2021-02-01
IL287084A (en) 2021-12-01
CN113966223A (zh) 2022-01-21
EP3952899A1 (en) 2022-02-16
AU2020270985A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
CY1123307T1 (el) Πρωτεϊνες συγχωνευσης fgf21 μακρας δρασης και φαρμακευτικες συνθεσεις που τις περιλαμβανουν
EA201391756A1 (ru) Композиции, содержащие, способы, включающие, и применение производных доластатина, связанных с неприродными аминокислотами
ES2346771T3 (es) Peptidos con multiples dominios a-helicoidales anfipaticos y procedimientos para su uso.
MX2019011004A (es) Compuestos y composiciones para la administracion intracelular de agentes terapeuticos.
Park et al. Activation of the mTOR signaling pathway in breast cancer MCF‑7 cells by a peptide derived from Porphyra yezoensis
WO2017049245A3 (en) Compounds and compositions for intracellular delivery of therapeutic agents
EA200001125A1 (ru) Гелеобразные фармацевтические композиции
WO2012069836A3 (en) Biologically active complex and its preparation
CN106456703A (zh) 铁调素模拟肽及其用途
RU2016135952A (ru) Композиции ингибитора дофа-декарбоксилазы
EA200870060A1 (ru) Эмульсия бутилфталида для внутривенного введения и ее применение
UY38068A (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
AR108631A1 (es) Formulación de neurotoxinas
CO2020008308A2 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
UY38067A (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
JP2018505146A5 (ru)
CO6620001A2 (es) Composiciones cosmeticas
DE602004017705D1 (de) Zusammensetzungen mit alphahydroxy-säureester zur wirkstofffreisetzung und anwendungsverfahren dafür
AR063263A1 (es) Agentes tensioactivos reconstituidos
EA202192792A1 (ru) Композиция для пероральной доставки белков, пептидов и малых молекул со слабой проницаемостью
CL2019003441A1 (es) Puestos de mic-1 y usos de estos.
AR093297A1 (es) Formulacion liquida que comprende un compuesto neutralizante de gm-csf
WO2016019333A1 (en) The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
EA202192925A1 (ru) Твердые формы ингибитора glyt1
JP6549554B2 (ja) コレステロール流出を刺激する、減少した毒性を有するペプチド